141 related articles for article (PubMed ID: 20102737)
1. Comparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in rats.
Yang W; Johnston KP; Williams RO
Eur J Pharm Biopharm; 2010 May; 75(1):33-41. PubMed ID: 20102737
[TBL] [Abstract][Full Text] [Related]
2. High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers.
Yang W; Tam J; Miller DA; Zhou J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2008 Sep; 361(1-2):177-88. PubMed ID: 18556158
[TBL] [Abstract][Full Text] [Related]
3. In vitro characterization and pharmacokinetics in mice following pulmonary delivery of itraconazole as cyclodextrin solubilized solution.
Yang W; Chow KT; Lang B; Wiederhold NP; Johnston KP; Williams RO
Eur J Pharm Sci; 2010 Mar; 39(5):336-47. PubMed ID: 20093186
[TBL] [Abstract][Full Text] [Related]
4. Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension.
Zhang K; Yu H; Luo Q; Yang S; Lin X; Zhang Y; Tian B; Tang X
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1285-92. PubMed ID: 23562534
[TBL] [Abstract][Full Text] [Related]
5. Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole.
DiNunzio JC; Miller DA; Yang W; McGinity JW; Williams RO
Mol Pharm; 2008; 5(6):968-80. PubMed ID: 19434851
[TBL] [Abstract][Full Text] [Related]
6. Single dose and multiple dose studies of itraconazole nanoparticles.
Vaughn JM; McConville JT; Burgess D; Peters JI; Johnston KP; Talbert RL; Williams RO
Eur J Pharm Biopharm; 2006 Jun; 63(2):95-102. PubMed ID: 16516450
[TBL] [Abstract][Full Text] [Related]
7. Flocculated amorphous itraconazole nanoparticles for enhanced in vitro supersaturation and in vivo bioavailability.
Miller MA; DiNunzio J; Matteucci ME; Ludher BS; Williams RO; Johnston KP
Drug Dev Ind Pharm; 2012 May; 38(5):557-70. PubMed ID: 21961961
[TBL] [Abstract][Full Text] [Related]
8. Solid dispersions of itraconazole and enteric polymers made by ultra-rapid freezing.
Overhoff KA; Moreno A; Miller DA; Johnston KP; Williams RO
Int J Pharm; 2007 May; 336(1):122-32. PubMed ID: 17184938
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic evaluation in mice of amorphous itraconazole-based dry powder formulations for inhalation with high bioavailability and extended lung retention.
Duret C; Merlos R; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Eur J Pharm Biopharm; 2014 Jan; 86(1):46-54. PubMed ID: 23523546
[TBL] [Abstract][Full Text] [Related]
10. Cryogenic liquids, nanoparticles, and microencapsulation.
Purvis T; Vaughn JM; Rogers TL; Chen X; Overhoff KA; Sinswat P; Hu J; McConville JT; Johnston KP; Williams RO
Int J Pharm; 2006 Oct; 324(1):43-50. PubMed ID: 16814968
[TBL] [Abstract][Full Text] [Related]
11. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release.
Kim JK; Park JS; Kim CK
Int J Pharm; 2010 Jan; 383(1-2):209-15. PubMed ID: 19747966
[TBL] [Abstract][Full Text] [Related]
12. NanoCluster Itraconazole Formulations Provide a Potential Engineered Drug Particle Approach to Generate Effective Dry Powder Aerosols.
Pornputtapitak W; El-Gendy N; Berkland C
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):341-52. PubMed ID: 25679514
[TBL] [Abstract][Full Text] [Related]
13. Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility.
Mou D; Chen H; Wan J; Xu H; Yang X
Int J Pharm; 2011 Jul; 413(1-2):237-44. PubMed ID: 21540090
[TBL] [Abstract][Full Text] [Related]
14. Enhanced pulmonary absorption of poorly soluble itraconazole by micronized cocrystal dry powder formulations.
Karashima M; Sano N; Yamamoto S; Arai Y; Yamamoto K; Amano N; Ikeda Y
Eur J Pharm Biopharm; 2017 Jun; 115():65-72. PubMed ID: 28223260
[TBL] [Abstract][Full Text] [Related]
15. Effect of hydrophilic additives on the dissolution and pharmacokinetic properties of itraconazole-enteric polymer hot-melt extruded amorphous solid dispersions.
Lang B; Liu S; McGinity JW; Williams RO
Drug Dev Ind Pharm; 2016; 42(3):429-45. PubMed ID: 26355819
[TBL] [Abstract][Full Text] [Related]
16. Characterization and pharmacokinetic study of itraconazole solid dispersions prepared by solvent-controlled precipitation and spray-dry methods.
Sim T; Lim C; Lee JW; Kim DW; Kim Y; Kim M; Choi S; Choi HG; Lee ES; Kim KS; Kang W; Oh KT
J Pharm Pharmacol; 2017 Dec; 69(12):1707-1715. PubMed ID: 28872678
[TBL] [Abstract][Full Text] [Related]
17. Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability.
Park YJ; Xuan JJ; Oh DH; Balakrishnan P; Yang HJ; Yeo WH; Lee MK; Choi HG; Yong CS
Arch Pharm Res; 2010 Aug; 33(8):1217-25. PubMed ID: 20803125
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability enhancement of itraconazole-based solid dispersions produced by hot melt extrusion in the framework of the Three Rs rule.
Thiry J; Kok MG; Collard L; Frère A; Krier F; Fillet M; Evrard B
Eur J Pharm Sci; 2017 Mar; 99():1-8. PubMed ID: 27951411
[TBL] [Abstract][Full Text] [Related]
19. Amorphization strategy affects the stability and supersaturation profile of amorphous drug nanoparticles.
Cheow WS; Kiew TY; Yang Y; Hadinoto K
Mol Pharm; 2014 May; 11(5):1611-20. PubMed ID: 24669821
[TBL] [Abstract][Full Text] [Related]
20. Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats.
Carvalho SR; Watts AB; Peters JI; Liu S; Hengsawas S; Escotet-Espinoza MS; Williams RO
Eur J Pharm Biopharm; 2014 Sep; 88(1):136-47. PubMed ID: 24859653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
